Brazilian pediatric doctor Monica Levi, one of the volunteers who accepted the COVID-19 vaccine, works at the Specialized Clinic in Infectious and Parasitic Diseases and Immunizations (CEDIPI), in Sao Paulo, Brazil, on July 24, 2020. The doctor is one of the 5,000 volunteers participating in Brazil of the configuration 3 trials – the last before homologation – of the ChAdOx1 nCoV-19 vaccine, developed by the University of Oxford together with the British pharmaceutical performers AstraZeneca.
Nelson Almeida | AFP | Getty Images
AstraZeneca shares turned negative Wednesday after a Brazilian haleness authority, Anvisa, said a volunteer in its coronavirus vaccine study died.
The Federal University of Sao Paulo, which is ration coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.
Shares of AstraZeneca, a front-runner in the Covid-19 vaccine competition, gave up a slight gain after the news broke. Shares were down by about 1% in early afternoon job.
A spokesperson from AstraZeneca declined to comment on the volunteer, citing “medical confidentiality and clinical trial regulations.”
The spokesperson augmented that “[a]ll significant medical events are carefully assessed by trial investigators” and “[t]hese assessments have not led to any concerns regarding continuation of the ongoing study.”
In a statement, a spokesperson from the University of Oxford, which is developing the vaccine with AstraZeneca, conveyed “there have been no concerns about safety of the clinical trial” after an assessment of the case in Brazil.
“The unconnected review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford spokesperson Alexander Buxton bring to light.
Oxford provided no further details on the volunteer’s death, and it’s unclear if the volunteer received the vaccine. Brazil currently has the assistant deadliest outbreak in the world, behind the United States, with at least 115,914 deaths, according to data gathered by Johns Hopkins University.
A source familiar with the situation told Reuters that the trial would compel ought to been suspended if the volunteer had been a part of the group getting the shot.
The news comes as the Food and Drug Charge still has a late-stage clinical trial from AstraZeneca on hold in the United States. That means the company is impotent to administer second doses of its two-dose vaccine regimen to U.S. participants.
The company announced on Sept. 8 that its headache had been put on hold due to an unexplained illness in a patient in the United Kingdom. The patient is believed to have developed inflammation of the spinal twine, known as transverse myelitis. The trial has since resumed in the U.K. and other countries.
The U.S. is expected to resume the trial as early as this week after the FDA completed its comment on, Reuters reported Tuesday, citing four anonymous sources.
AstraZeneca is one of four drugmakers backed by the U.S. in late-stage assessing for a potential vaccine. AstraZeneca’s vaccine, called AZD1222, uses genetic material from the coronavirus with a remodeled adenovirus.
In July, the company published data that showed its vaccine produced a promising immune response in an early-stage experimental and appeared to be well tolerated.
The vaccine produced no serious adverse events in volunteers, according to the researchers at the time. Weakness and headache were the most commonly reported side effects, they said. Other common side for all practical purposes included pain at the injection site, muscle ache, chills and a fever.